The emerging tech universe has grown from an NFT-focused evolution of the Internet to an interconnected but decentralized system built on blockchain-based supply chain management and community-based ownership protocols, and this year’s BREATHE! Convention at The Expo @ World Market Center Las Vegas is the place to go exploring.

Developers, collectors, investors and educators, will all gather at this convention to network and revolutionize tech-centric industries September 13 through 15, at one of the premier convention centers in the heart of Downtown Las Vegas, Nevada.

Subject matter experts and educators at BREATHE! are not charged or paid to speak at the event — they are chosen by the event organizers at 5AM Global based on their merit, expertise, and engagement skills.

“This allows BREATHE! to provide communicative value that is delivered by passionate and active members of the emerging tech space,” the event’s white paper outlining its undergirding principles states. The expert speakers are allotted time slots on varying stages that suit the needs and interests of attendees and participants.

Aaron Vick, for example, has been driven to build in Web3’s global landscape since 2017, teaching how Web3’s increased capacity for transparency, accountability, and sustainability, can provide the foundations for a strong communal culture.

Billy Womack, an advisory board member for BREATHE!, has established a track record of success inside and outside the blockchain and cryptocurrency industry over the past quarter century, specializing in blockchain software nodes to a degree that many blockchain companies and investors have come to consider him the number one independent software node consultant in the world.

And crypto content creator Deezy, the CMO of Voomio, has helped launch NFTs on several chains, hosting Around The Blockchain and providing entertaining insights through Twitch.

Key Takeaways:

• BREATHE! will take place in a world-leading convention space located in the heart of Las Vegas’ city of lights — a crossroads of global entertainment and business networking
• The BREATHE! convention will feature an anticipated 5,000 attendees, more than 80 speakers, and will provide a display floor for more than 200 brands
• The event will provide education, networking opportunity and entertaining community spaces that includes innovations in augmented reality, virtual reality and new levels of gameplay possibilities
• BREATHE! specializes in enabling attendees to pursue channels focused on decentralized finance (Defi), crypto universes, and non-fungible tokens (“NFTs”), but all under one roof
• The convention’s Villages concept provides a nexus of activity for projects and companies invested in emerging tech-related services and technologies

Maintaining the Machinery:

BREATHE! is operated by strategic marketing and business management firm 5AM Global, with strategic event collaborators in the United Kingdom, Israel, France, Qatar, and Dubai, plus a globally connected advisory board of subject matter experts and educators.

BREATHE! Convention is powered by Metakeep and NFT-TiX

For more information about this event, please visit https://ibn.fm/BOrqR.

• Prospera’s holdings include significant remaining reserves totaling an estimated half a billion barrels of oil across more than 42,000 acres in Saskatchewan and Alberta
• Following a top-down reorganization in 2021, the company is poised to rapidly expand its production in the coming months while implementing key ESG initiatives to reduce the environmental footprint of its operations
• Prospera is exploring a potential acquisition opportunity that could see its production capacity expanding beyond 5,000 barrels per day
• The company is led by a team with extensive, diverse petroleum industry experience and a proven track record of reorganizing organizations, structuring financing arrangements and positioning for growth

Prospera Energy (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B) is a public oil and gas exploration, exploitation and development company focusing on conventional oil and gas reservoirs in Western Canada. The company uses its experience to develop, acquire and drill assets with potential for primary and secondary recovery.

Prospera is primarily focused on optimizing hydrocarbon recovery from legacy fields through environmentally safe and efficient reservoir development methods and production practices. It is in the midst of a three-stage restructuring process aimed at prioritizing cost effective operations while appreciating production capacity and reducing liabilities.

The company is based in Calgary, Alberta, Canada.

Operations

Prospera’s core properties include more than 42,000 cumulative acres across Cuthbert, Luseland and Heart Hills in Saskatchewan and Red Earth and Pouce Coupe in Alberta. In total, the company estimates that there are half a billion barrels of oil in place at these sites accounting for 20+ years of forward project lifespan, with as little as 8% of total reserves having been recovered via legacy vertical well technology.

Restructuring Initiative

In 2021, Prospera enacted a top-down reorganization. The early results of these efforts were on display in May 2023, when the company reported a three-fold year-over-year increase in annual revenue for 2022 alongside drastically reduced operating costs and record-high cash flow from operations.

Prospera noted in the news release that it has positioned itself in 2023 to execute the second phase of its development plan aimed at increasing production through medium-oil development in Alberta and leveraging horizontal wells to capture the significant remaining reserves in Saskatchewan.

During the company’s investor summit in August 2023, Prospera CEO Samuel David provided more information regarding this three-phase strategy:

Phase I

Prospera completed the first phase of its restructuring by optimizing operations at its existing assets and addressing legacy arrears and non-compliance issues.

At the beginning of this transformation, the company was producing just 80 barrels of oil equivalent (“BOE”) per day. In Q4 of last year, Prospera peaked at nearly 1,200 BOE per day. Its breakeven is around 500 barrels per day, illustrating the opportunity for free cash flow. This prospect has driven Prospera’s capital development and optimization in recent quarters.

After a temporary slowdown in production due to harsh winter conditions, Prospera is currently producing about 800 BOE per day and anticipates an additional 300-500 barrels of daily production following the completion of ongoing site maintenance work.

This sustained increase has pushed the company’s NPV from roughly $3 million prior to the restructuring efforts to approximately $72 million today.

In an effort to build on this progress and maximize its available resources, Prospera piloted two horizontal reentries to assess a potential horizontal well transformation at its properties.

Phase II

Following up on the optimization efforts of Phase I, Prospera aims to commence a horizontal well transformation at its properties in the coming months. Based on its pilot wells from Phase I, the company has proposed 10 horizontal well locations at its Cuthbert and Heart Hills properties.

Prospera has likewise proposed eight medium light oil direction wells at its Alberta property, and it is exploring strategic acquisitions aimed at expanding its core area and diversifying its product mix.

Other facets of Phase II include piloting an enhanced oil recovery (“EOR”) application and continuing to execute its liability management goals and ESG initiatives. Prospera has already abandoned 60 vertical wells as part of its three-year LMR plan to reclaim surface land and reduce the environmental footprint of its operations.

Phase III

Beginning next year, Phase III of Prospera’s corporate redevelopment strategy will focus on continuing the company’s horizontal modular development to appreciate production and optimize recovery of remaining reserves. Prospera intends to implement full-scale EOR applications based on the results of its Phase II pilot program, which is forecast to optimize recovery by greater than 10%.

Prospera also intends to continue its acquisition strategy to diversify its product mix. Its goal, as detailed by in August 2023 investor summit, is to attain 50% light oil, 40% heavy oil and 10% gas – all while continuing to eliminate carbon emissions as part of its existing ESG initiatives.

Poised for Growth

Following its transformational efforts in 2022, Prospera is poised to achieve record growth in 2023. The company has forecast significant reductions in production costs through 2024, alongside sizable increases in daily production.

Prospera is currently exploring strategic acquisition targets to potentially increase its production beyond 5,000 BPD while expanding its reserve base to a billion barrels.

Market Opportunity

While the oil and gas industry faces long-term geopolitical and macroeconomic uncertainty, there is a clear trend to secure supply in the short term. According to Deloitte, the global upstream industry ended 2022 with some of the highest free cash flows on record, driving reinvestment in hydrocarbons and overall investment in clean energy.

The Energy Information Administration recently forecast a dip in global oil inventories over each of the next five quarters, placing upward pressure on oil prices. The agency further forecasts a YoY increase in fuel consumption, exacerbating the effects of OPEC+ production cuts that are set to remain in place through 2024.

For Prospera, these forecasts are promising. The company aims to build on its recent financial growth in the coming months (Prospera reported a three-fold YoY increase in revenue to $13.9 million in 2022), hitting a projected $57 million in total revenue by the end of 2024 while working to expand its core area holdings through accretive M&A transactions.

Leadership Team

Prospera is led by a team with extensive, diverse petroleum industry experience spanning both reservoir management and operations of oil and gas assets. The team boasts a proven track record of reorganizing companies, structuring financing arrangements and positioning for growth.

Samuel David is the company’s President and CEO. He brings to Prospera over 32 years of experience in operation, development and management of oil and gas assets and companies. Mr. David holds a B.Sc. in Mechanical Engineering and a B.A. in Economics from the University of Calgary. His background consists of both engineering and executive management experience with majors Petro-Canada, AEC Oil & Gas (now EnCana / Cenovus) and Husky Energy, as well as founding and operating juniors Ventura Energy and First West Petroleum. Mr. David has proven expertise in corporate planning, production, reservoir engineering, depletion strategies, EOR, property evaluations, acquisitions and divestitures.

George Magarian is VP Subsurface for Prospera. He is a professional petroleum geologist (“APEGA”) with over 36 years’ experience in the Western Canada Sedimentary Basin. After graduating with an Honors B.Sc. degree in Earth Science from the University of Waterloo, Mr. Magarian spearheaded many successful exploration programs, conducted evaluations for improved recovery schemes and assessed/exploited unconventional oil reservoir opportunities. He has held roles of increasing responsibility, from exploration geologist at oil industry major Petro-Canada and intermediates Anderson Exploration and Jordan Petroleum, to geoscience manager and VP exploration at junior companies Ionic Energy, Gentry Resources and Westfire Energy.

Chris Ludtke is the company’s VP Finance & Accounting. He is a high functioning finance leader with extensive expertise in finance, budgets and planning, accounting, economic evaluation, management, governance and sound decision making. Mr. Ludtke has 20 years of experience within the oil and gas, clean energy and renewables industries, including 12+ years working for Husky Energy before moving into an executive role in the junior oil and gas and hydrogen space. He graduated from the University of Lethbridge (Bachelor of Management) and is a Chartered Professional Accountant in the Province of Alberta.

Matthew Kenna is the CFO of Prospera. He has over 30 years’ experience leading organizations and helping them expand, drive efficiencies and grow profitability. Mr. Kenna is a professional accountant (CPA, CMA) and spent 15 years heading up the financial and operating departments at KUDU Industries, where he fostered financing arrangements, client relationships and manufacturing teams to take the organization from $35M to $150M in revenue. He has extensive experience turning companies around, growing them and building efficient organizations.

For more information, visit the company’s website at www.ProsperaEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to GXRFF are available in the company’s newsroom at https://ibn.fm/GXRFF

• D-Wave and Davidson revealed new joint applications focused on interceptor assignment and optimized radar scheduling at the recent Space and Missile Defense Symposium
• The companies are working together to advance intelligent technology solutions for the defense and aerospace industries, creating applications that could support a variety of mission objectives

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, has announced that progress has been made in a collaboration with Davidson Technologies, Inc., a technology services company that provides innovative engineering, technical, and management solutions for the Department of Defense, aerospace, and commercial customers. The collaboration between D-Wave and Davidson is intended to create solutions that advance national defense efforts. Both companies were present at the Space and Missile Defense Symposium, revealing that together, they have built two applications – focusing on interceptor assignment and optimized radar scheduling (https://ibn.fm/XU9oE).

The interceptor assignment application is designed to mitigate potential attacks and can take into account multiple complex variables. These include missile capability in negating threats, a balanced allocation of missiles to threats, and the availability of resources to help quickly identify potential defense threats and key mitigation tactics. The radar scheduling application efficiently manages the time-limited resources of a phased-based array radar system and enables scheduling communication with moving objects.

“During times of military response, speed matters, and our artificial intelligence, powered by D-Wave’s technology, provided an answer much faster than other computational options,” said Major General John W. Holly (US, Ret.), president, CEO, and Chairman of Davidson. “Our mission is to deliver advanced, agile technology solutions in defense of our Nation, and together with D-Wave, we’re providing our government customers with critical applications in service to our country.”

D-Wave and Davidson have been collaborating since August 2022, when they entered into a multi-year reseller agreement that allows Davidson to resell D-Wave’s products and services – including Leap(TM) quantum cloud services. Leap allows developers proficient in Python to start building and running quantum applications. Users can easily start solving complex problems of up to one million variables and 100,000 constraints through a seamless and secure cloud-based connection.

Leap delivers immediate, real-time access to D-Wave’s Advantage(TM) quantum computer and quantum hybrid solver service – all with enterprise-class performance and scalability. By using Leap, D-Wave’s customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail, and transportation. These use cases can be found within the company’s customer success stories (https://ibn.fm/P6eDy).

“By utilizing emerging and advanced technologies, Davidson is able to provide its customers with unique military implementation and national defense tools,” said Dr. Alan Baratz, CEO of D-Wave. “We share that spirit of imagining the unimaginable and harnessing the power of technology to keep America safer. We are excited to see advancement in our collaboration and look forward to more robust application development over our multi-year relationship.”

D-Wave and Davidson are working together to advance intelligent technology solutions for defense and aerospace industries, creating applications that could support a variety of mission objectives, including, but not limited to, supply chain management, logistics management, weapon system optimization, and vehicle routing. D-Wave’s solutions are available now through its Leap quantum cloud service and work alongside other technologies like high-performance computing and artificial intelligence and machine learning (AI/ML).

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding the collaboration between D-Wave and Davidson and the results thereof. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including general economic conditions and other risks; D-Wave’s ability to expand D-Wave’s customer base and the customer adoption of D-Wave’s solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of D-Wave’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of D-Wave’s products; the effects of competition on D-Wave’s business; the risk that we will need to raise additional capital to execute D-Wave’s business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect D-Wave’s intellectual property; volatility in the price of D-Wave’s securities; the risk that D-Wave’s securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

• RJD Green announced in May 2023 that its Silex Holdings division had been awarded a major commercial contract worth over $850,000
• For the three months ended May 31, 2023, the company reported revenue of $1.42 million and $290,071 in net operating income
• RJD Green revenue projections for the fiscal year ending August 31, 2023, are $5.1 million, with an expected net profit of $727,250
• The company has monthly recurring revenues of $415,254

RJD Green (OTC: RJDG) is a holding company focused on managing portfolio assets while actively exploring potential acquisitions and opportunities in diversified industries. The company currently operates in three divisions: RJD Green Healthcare Division, Earthlinc Environmental Solutions and Silex Holdings Inc.

The company’s corporate management team has a history of success in both public and private arenas, with diverse enterprise experience that includes RJD Green’s three current market sectors of focus. Corporate overhead is maintained at minimal operating cost, with each officer and team member maintaining daily management responsibility for specific operating divisions and entities.

Each acquisition and asset is operated as a separate profit center, with the recognition that, in small business operations, proficiency and frugal budgeting are required to maximize profitability. The RJD Green team excels in working collaboratively with the company’s business partners, creating common efforts for reaching mutual reward from its relationships.

The company is headquartered in Tulsa, Oklahoma.

Business Divisions

RJD Green Healthcare Division

Through this division, the company has developed a business model that utilizes the healthcare industry experience and extensive industry relationships of its management team. RJD Green’s leadership has long-term relationships with many key providers within the service sectors of the healthcare industry.

The first RJD Green Healthcare Division services acquisition was IoSoft Inc., a company that provides discrete payment technologies, services and software that can be integrated into targeted offerings for healthcare provider networks, hospitals, healthcare payers and individual providers. The IoSoft team has years of experience and relationships within the more than a million providers in the healthcare market.

Earthlinc Environmental Solutions

This division was formed to promote green applied technologies and offer environmental services in North America. Its focus is on performance-driven solutions for environmental-based issues.

The first acquisition, Animal Waste Management, is a patented technology that is fully developed and entering the market for waste processing on commercial chicken and hog farms. Development was supported by the University of Arkansas and the Missouri Department of Natural Resources.

The acquired technology controls the liquid, solid and gas waste generated, creating an odorless, clean, bacteria-free by-product that can be used for animal feed filler, while allowing the water to be reused as ground water on the farm.

Silex Holdings Inc.

This division was formed for the purpose of acquiring and managing high growth assets and business enterprises. Its operations are focused on acquisitions in specialty industrial contracting, building material products and construction services.

Acquisitions are modeled to offer immediate growth, such as a unique geographical or proprietary market niche or other differentiating quality, and are synergistic in corporate management and administration, as well as sales and marketing.

The company’s first acquisition through this division, Silex Interiors, is a manufacturer, distributor and installer of countertops, cabinets and related kitchen and bath products. Silex is modeled for expansion into major markets nationally through internal expansion, acquisition and franchising.

Market Opportunity

According to a report from Reportlinker.com, the global healthcare services market is expected to grow from $6.8 billion in 2021 to $10.4 billion in 2026 at a CAGR of 8.6%. The report attributed the forecast growth primarily to healthcare companies restructuring their operations as a result of lasting challenges presented by the COVID-19 pandemic.

Research firm Verdantix reported the environmental services market was worth an estimated $35.2 billion in 2022 and is expected to reach a value of $50.6 billion by 2029, marking a CAGR of 6.3% for the forecast period. Verdantix identified factors driving growth to include changing environmental compliance regulations, rising demand for infrastructure projects and increased ESG reporting scrutiny.

In 2021, Icon Market Research estimated the global specialty trade contractors market at $3.9 billion, forecasting that it will reach $5.7 billion by 2028 at an expected CAGR of 9.2% through the identified period.

Management Team

Ron Brewer is CEO of RJD Green. He has served as a corporate officer in both public and private companies, including as president of Mid-Continent Companies. He has experience in all three industries represented by the company’s divisions. He has provided management and guidance to five environmental services and technology companies, as well as guiding business development services in healthcare for hospitals, practice assistance and various service providers in the sector. He has also developed three separate companies in the same construction products sector.

Jerry Niblett is COO at RJD Green. He has over 19 years of management success in oil and gas operations at both corporate and small-cap enterprises. His corporate employment history includes Dominion Energy, Texaco, Shell and Sunoco Pipeline LP. He has worked in multiple energy sectors, including petro-chemical refining, natural gas compression, crude oil pipeline and storage, oil and gas exploration, and oil and gas products and services business development. He holds a bachelor’s degree in Total Quality Management, graduating with honors.

John Rabbitt is CFO at RJD Green. He has worked at Fortune 500 firms including Pillsbury, PepsiCo and CPA firm Ernst and Ernst. He played a key role in the growth of MEI Corp. from $20 million annual revenue to $850 million annually in nine years, at which time it was acquired by PepsiCo. He has a proven track record in both fast-growth and turnaround environments, serving in CEO/COO and CFO positions for firms ranging from $5 million to $300 million annual revenue. His education includes degrees in accounting and business from Drake University and PepsiCo’s Management Institute.

For more information, visit the company’s website at www.RJDGreen.com.

NOTE TO INVESTORS: The latest news and updates relating to RJDG are available in the company’s newsroom at https://ibn.fm/RJDG

• GEMXX Corporation, a U.S. corporation with mines in Canada, is a mine-to-jewelry production innovator, drawing on its mining assets for the gold and gems it uses in colorful jewelry
• GEMXX recently engaged the marketing and brand expertise of Hybrid Financial Ltd. as the company seeks to expand awareness of its novel operations in gold and rare gem Ammolite
• GEMXX similarly is working with InvestorBrandNetwork (“IBN”) to expand awareness of the company through IBN’s syndication outlets, wire services and other corporate communication efforts
• The company is preparing to perform National Instrument 43-101 and S-K 1300-compliant Resource Reports on two of its Ammolite assets, and the British Columbia gold operations in which GEMXX acquired a 50 percent stake earlier this year

Mine-to-market global jewelry producer GEMXX (OTC: GEMZ) is polishing its operational profile with news of its progress in efforts to finance its gold and ammolite mining operations and expand its brand awareness in public trading markets.

GEMXX recently announced that new investment has strengthened its financial position and provided new energy to fulfilling its growth strategy while it works to select an engineering firm best suited to conducting National Instrument 43-101 reports on its assets (https://ibn.fm/OxUrw).

The company subsequently engaged Hybrid Financial Ltd. to provide marketing and brand awareness services that it expects to attract further investment over the next 12 months, particularly through a Reg A offering that is fully qualified for $6 million at 40 cents ($0.40 USD) per share (https://ibn.fm/Q7FC5).

GEMXX has also welcomed the corporate communications expertise of InvestorBrandNetwork (“IBN”) for expanding its brand awareness through IBN’s investor-based distribution network of over 5,000 syndication outlets, newsletters, social media channels, wire services and blogs, as announced earlier this month ((https://ibn.fm/pAdPG).

GEMXX stands out as a company that mines its own gold reserves for use in its jewelry production, which provides the company an edge in cutting its costs.

In March, the company announced it had acquired a 50 percent ownership stake in Canadian gold mining company Crazy Horse Mining Inc. Crazy Horse’s assets include a 100 percent interest in the Snow Creek and Rosella Creek gold projects, which are spread across more than 700 acres in British Columbia (https://ibn.fm/1SQYx).

Crazy Horse estimates it can easily recover more than 100,000 ounces of gold from the sites, and has scheduled an S-K 1300-compliant Resource Report to provide a more comprehensive assessment of its estimate.

GEMXX also mines a rare gem called Ammolite for its jewelry — a gem similar to black opal that is derived from the fossilized shells of ammonites, a group of extinct marine nautiluses, that lend distinctive color arrays to the company’s products.

The gemstones come from deposits in Alberta, Canada.

“We are tremendously pleased with the development of the Company over the past several months and we are extremely excited for the anticipated growth,” CEO Jay Maull stated in May (https://ibn.fm/mpKSK).

For more information, visit the company’s website at www.GEMXX.com.

NOTE TO INVESTORS: The latest news and updates relating to GEMZ are available in the company’s newsroom at https://ibn.fm/GEMZ

• Tin has become an increasingly important commodity within the renewable energy supply chain
• Nonetheless, supply of the commodity is heavily concentrated, with over 60% of global supply accounted for by only three nations
• The metal’s tenuous supply picture was most recently on display in early August when militia officials in Myanmar – the third largest global tin producer – unilaterally shut down many of the country’s tine mines
• Eloro Resources’ Iska Iska deposit may emerge as one of the most significant contributors to global tin supply in the coming years, with the company set to publish their inaugural NI 43-101 compliant mineral resource estimate (“MRE”) by the end of August

In medieval times, tin was an instrument of war. Dating back to the metal’s original role in the manufacture of weapons and armor – oftentimes in the form of bronze – through to the use of tin plates in the seventeenth century to provide corrosion resistance to iron and steel, tin has played a crucial role within the global industrialisation movement for hundreds of years. Nowadays, tin is primarily utilized as a soldering mechanism to create electrical connections, a function accounting for nearly 50 percent of demand for the commodity. Put simply, every component of the low-carbon and increasingly data-driven economy requires tin: without it, electrons don’t flow – meaning mobile phones would not work, electric vehicle batteries would fail to charge, and the Internet of Things would cease to exist.

The global march towards Net Zero, an ambition predicated on the world achieving a balance between global greenhouse gas (“GHG”) emissions and those being removed from the atmosphere by 2050, has now emerged as the biggest long-term demand driver of tin. With energy increasingly delivered to goods via a battery-connected wire (as opposed to a cable linked to electricity mains), incremental quantities of tin will be required to facilitate these connections. Similarly, factors such as the rising adoption of 5G networks, the exponential growth of the Internet of Things, as well as the addition of tin within lithium-ion battery anodes to slow degradation are all likely to contribute to making the metal an integral variable in terms of delivering a low-carbon future.

Nonetheless, tin does not come without its risk. Over 50 percent of global tin supply currently originates from China and Indonesia; Myanmar is third-largest supplier whilst the Democratic Republic of Congo – more often cited for its role within the global cobalt supply chain, is rapidly gaining share. The supply chain risk was most recently illustrated by a tin mining ban imposed by Myanmar’s Wa State militia. Myanmar’s Wa region, located in the country’s north-east, accounted for over 70% of Myanmar’s tin production in 2022; the regional militia, the most powerful ethnic armed group in the country, ordered a blanket ban on tin production as of the 1st of August in a bid to ‘protect the remaining mineral resources in the state’ (https://ibn.fm/nJBpH). Since reports of the mooted ban were first circulated in early April 2023 through to its implementation at the start of August, tin prices have risen by nearly 17 percent, outpacing copper and gold by over 22 percent and 25 percent over that interim.

Eloro Resources (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec, is one of the company’s seeking to fill the incremental supply gap. Eloro Resources has recently carried out a number of metallurgy studies linked to its flagship Iska Iska deposit; recent tests have revealed its key deposit to contain two extensive areas of potential mineralization – split into areas focused around silver-tin and silver-zinc-lead, respectively.

Early tin optimization tests carried out at the facilities of consulting group, Wardell Armstrong International in Oruro, Bolivia have revealed the possibility of employing ‘ore sorting’ to extract tin from the deposit. Ore sorting, a procedure entailing the identification and removal of waste and below-grade ore to pre-concentrate the ore being processed, is a key manner through which mining companies can calculate the economic feasibility of extracting a resource from the ground. In Eloro’s case, initial test results suggest that as much as 80% of the tin ore weight may be rejected on an ex-ante basis as sub-cut-off grade waste. In effect, ore sorting can assist Eloro in increasing concentrator feed grades, thereby increasing the recovery of actual ore post the processing stage and reducing downstream processing costs (https://ibn.fm/YLvYJ).

With the global tin market projected to reach an annual size of 481.9 thousand tons by 2030 – implying a 4.5% CAGR growth rate over the next 7 years (https://ibn.fm/HKRqY), securing a reliable supply stream of the commodity has gained increased relevance for companies and manufacturers the world over. With Eloro expected to publish its inaugural mineral resource estimate (“MRE”) at the end of August, the miner may soon affirm its place as an integral member of the metal’s global supply chain.

Mike Hallewell, C.Eng, Eloro’s Senior Strategic Metallurgist commented in relation to the company’s upcoming MRE report: “The level of metallurgical and pyrometallurgical work that has been conducted thus far at Iska Iska is exceptionally high for an inaugural MRE but is justifiable due to the significance of this large potentially open pittable tin and polymetallic resource. This additional metallurgical/mineralogical knowledge will enable Eloro to rapidly move towards a preliminary economic assessment (‘PEA’).”

For more information, visit the company’s website at www.EloroResources.com.

NOTE TO INVESTORS: The latest news and updates relating to ELRRF are available in the company’s newsroom at https://ibn.fm/ELRRF

• Innovative nanobody therapeutics could deliver substantial competitive advantages in both cost and efficacy when compared to traditional monoclonal antibody therapies
• The biologics market was valued at $366.5 billion in 2021 and is expected to grow to a value of $719.94 billion by 2030
• The monoclonal antibodies market was valued at $210.06 billion in 2022, and it is expected to reach $494.53 billion by 2030
• The nanobody market was valued $237.1 million in 2021 and is expected reach a value of $1.07 billion by 2028
• BiondVax is uniquely positioned to rapidly advance from R&D towards commercialization

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is planning a rapid development path that leverages the company’s expertise and capabilities in biological drug development and manufacturing. Using a platform of alpaca-derived nanobodies (NanoAbs), BiondVax is targeting large market disorders underserved by current therapeutics, including COVID-19, asthma, and psoriasis. BiondVax’s diverse and growing pipeline is being developed in collaboration with the world renowned Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”) in Germany.

The biologics market, which is comprised of any pharmaceutical drug product manufactured in, extracted from, or semi-synthesized from biological sources, was valued at $366.5 billion in 2021 and is expected to grow at a CAGR of 7.15%, resulting in a value of $719.94 billion by 2030. The introduction of targeted therapies and the rising adoption of patient-centric personalized medicine is anticipated to drive the market growth (https://ibn.fm/B5964). The increased demand for biologics is expected to further drive the monoclonal antibodies market size, valued at $210.06 billion in 2022 and expected to reach $494.53 billion by 2030, growing at a CAGR of 11.04% (https://ibn.fm/DbI81).

Leveraging its innovative NanoAb platform, BiondVax is penetrating a market with an eye-popping projected CAGR of 24.1% and quadrupling in value to $1.07 billion in five years. (https://ibn.fm/dUZ7G). NanoAbs offer significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration, and efficient production – BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

BiondVax’s pipeline development remains the company’s core focus. In addition, it recently announced expanding its offering of services as a boutique end-to-end contract development and manufacturing organization (“CDMO”). The CDMO services allow BiondVax to partner with pharmaceutical companies to provide contract-based drug development and manufacturing services. The new service offering allows the company to use its proven experience running pre-clinical trials, clinical trials, chemistry, manufacturing, and more to accelerate development of their clients’ products.

“Offering CDMO services allows us to use our state-of-the-art facility to generate revenues and offset certain fixed costs while still using it for our NanoAbs,” BiondVax CEO Amir Reichman said in a recent interview (https://ibn.fm/G4NnO).

The company has shown incredible initial results and enormous promise with its innovative Covid-19 treatment.  It has built a state-of-the-art biopharmaceutical product manufacturing facility that houses laboratories, production facilities, and offices. The BiondVax team also includes highly experienced and successful pharmaceutical industry leaders, including former senior executives from Novartis, GSK, and Bristol-Myers Squibb.

With the rising adoption of biopharmaceuticals over chemically synthesized molecules, the biologics market (which encompasses monoclonal antibodies and nanobodies) is expected to grow significantly and propel revenue potential. BiondVax is positioned to disrupt the market with its innovative and potentially block buster NanoAb therapeutics.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• Ucore recently announced the closing of the first tranche of its previously announced private placement offering of units of the company
• On June 6, the company announced that the U.S. DOD had awarded it a $4 million project grant
• Together, these moves bolster Ucore’s working capital and continue to stamp its position as a leader in its space
• Through its investments, Ucore is inching closer to taking over the global rare earth elements market, which is expected to hit $5.6 billion by 2025

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a company engaged in the exploration for and separation and scalable production of rare earth elements (“REEs”) in Canada and the U.S., is, through its many strategic efforts, building itself to become a major leader in its sector. Just recently, the company announced the closing of the first tranche of its previously announced private placement offering of units of the company, for aggregate gross proceeds of $4,409,500, in what is set to be a key catalyst in advancing its RapidSX(TM) REE commercial demonstration plant in Kingston, Ontario (https://ibn.fm/kcaNI).

“We believe that Ucore’s Kingston, Ontario, Demo Plant is currently the largest heavy REE separation plant in North America,” noted Mike Schrider, Ucore’s Vice President.

“It is capable of processing tens of tons of light and heavy REEs utilizing the exact same equipment – and represents a unique technological advantage,” he added (https://ibn.fm/Xn03z).

On June 6, Ucore announced that the U.S. Department of Defense (“DOD”) had awarded it a $4 million project grant. The move showed that Ucore and RapidSX(TM) could meet government benchmarks, even as the company continues establishing an alternative supply chain for REEs independent of the People’s Republic of China (https://ibn.fm/9LEFE). This, coupled with the first tranche private placement, not only bolsters Ucore’s working capital but also continues to stamp its position as a leader in its space.

China controls over 36.7% of the world’s REE reserves, 63% of its mining capacity, and over 90% of its refining capacity. Ucore is out to eat into this market share and assert dominance and independence from this supply chain (https://ibn.fm/k7qM4). Through its tried technology, the company has won over the U.S. government. With its aggressive yet strategic investments, the company is on track to create a critical metals (“CM”) supply chain independent of China.

So far, Ucore has invested over C$35 million to establish and validate the Bokan-Datson Ridge resource. Its additional investments throughout North America continue to inch the company closer to taking over the global rare earth elements market, which is expected to be valued at $5.6 billion by 2025. In addition, these investments continue to prop Ucore to be the leading global metal separation products and services provider, ultimately creating value for its shareholders.

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• Recent report projects estimated growth of tellurium market at CAGR of 3.41% between 2022 and 2027
• Growth is tied to increased demand from the consumer electronics industry
• Company’s unique approach offers significant advantages over larger mines

With recent market projections showing steady growth in the tellurium market (https://ibn.fm/11Lg4), First Tellurium’s (CSE: FTEL) (OTCQB: FSTTF) small-mine, phased-approach strategy is sure to strengthen the company’s position in the growing space.

“The tellurium market is estimated to grow at a CAGR of 3.41% between 2022 and 2027,” a 2023 Technavio analysis study reported. “The size of the market is forecast to increase by 83.72 MT.” The report went on to take a closer look at the tellurium market based on application (solar panels, thermoelectric production, metallurgy and others), type (pure tellurium and telluride), and geography (APAC, North America, Europe, South America, and the Middle East and Africa).

“The increased demand from the consumer electronics industry is notably driving market growth,” stated the report. “Tellurium alloys are commercially used in various consumer electronics products. They offer potential solutions to a wide range of applications such as mobile phones, LED displays and projectors, wearable electronic devices, gaskets and lighting, and rollers.

“Additionally, factors such as the increasing urban population, rise in disposable income, strong supply chain and high internet penetration also drive the growth of the global market,” the report continued. “Furthermore, the governments of many developing countries are providing exemptions on certain duties to boost the manufacturing capacity of consumer electronics manufacturers. Therefore, the high demand for this product will drive market growth during the forecast period.”

First Tellurium has worked hard to become a leader in this space. The company’s strategy is to start with a small mine and expand it over time (https://ibn.fm/jkOsq). The company is currently North America’s leading tellurium explorer with its Klondike tellurium-gold property in Colorado and polymetallic Deer Horn Project in British Columbia.

“A key driver of this strategy is Indigenous support, including potential investment and employment,” the company states on its website, noting that its unique approach offers significant advantages over larger mines, including lower exploration/development costs, significantly lower CapEx (only $28.3 million), faster time to production and cash flow, and exceptional post-tax payback (1.6 years). In addition, First Tellurium is able to deliver faster to buyers, has potential dilution-free funding for resource development along with a more simple permitting with a small mine application and a smaller environment footprint.

First Tellurium’s business model is designed to generate revenue and value through mineral discovery, project development, project generation and cooperative access to untapped mineral regions in Indigenous territory with sustainable exploration. “This is the future of mineral exploration: generating revenue by exploring responsibly and leveraging diverse partnerships,” the company stated. “First Tellurium proudly adheres to and supports the principles and rights set out in the United Nations Declaration on the Rights of Indigenous Peoples and in particular the fundamental proposition of free, prior and informed consent.”

For more information, visit the company’s website at www.FirstTellurium.com.

NOTE TO INVESTORS: The latest news and updates relating to FSTTF are available in the company’s newsroom at https://ibn.fm/FSTTF

• In June 2023, Renovaro announced that a potential IND application for its innovative cancer platform is on track for early 2024 FDA submission
• The company in March 2023 announced proof-of-concept for its proprietary technology to treat pancreatic tumors
• In August 2023, Renovaro announced its entry into a Letter of Intent to merge with GEDi Cube International Ltd. with the aim of accelerating diagnosis, enhancing treatment effectiveness, discovering new therapies, and expanding access to life-saving technologies for cancer and other diseases
• As of August 2023, Renovaro has raised total cash of $82.7 million
• The company’s IP portfolio covering gene and gene-modified cell therapies includes patents, patent applications and licensed technologies under patent application

Renovaro BioSciences (NASDAQ: RENB) formerly Enochian BioSciences Inc., is an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy. The company aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers, and to potentially treat or cure serious infectious diseases such as Human Immunodeficiency Virus (“HIV”) and Hepatitis B Virus (“HBV”) infection.

The oncology platform is now at the forefront of Renovaro’s development activities. While Renovaro’s current efforts focus primarily on pancreatic cancer, it plans to include other solid tumors with short life-expectancy in the first in human Phase I/IIa studies that are on track to start by mid-2024. The company’s Pre-Investigational New Drug (pre-IND) submission included a human study plan covering pancreatic cancer, as well as other cancers that are difficult to treat, potentially including triple-negative breast cancer, head and neck cancers and mesothelioma.

Renovaro’s proprietary, novel technology uses cell- and gene-therapy to promote a renewed immune response against solid tumors. Important confirmatory results from two humanized mouse models using the company’s novel dendritic cell-based therapy, independently conducted by Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy at UCLA, were presented previously at two scientific conferences and were the foundation supporting a pre-IND submission to the U.S. Food and Drug Administration. Notably, Dr. Jewett’s findings from these studies consistently demonstrated 80% to 90% pancreatic tumor reduction in size and weight that was correlated with significant enhancement of key aspects of the immune response.

Renovaro is headquartered in Los Angeles, California.

RENB-DC11

Renovaro’s product development strategy is anchored in the use of “non-self” or allogeneic cells that enhance targeted immune response. Its lead candidate, RENB-DC11, is an innovative therapeutic vaccination platform that could potentially be used to induce life-long remissions from some of the deadliest solid tumors.
Treatment with RENB-DC11 has now been shown to significantly reduce the size of human pancreatic tumors in humanized mice in three independent studies. The reduction in tumor size correlated with statistically significant increases in key components of an immune response.

Pre-IND was completed in June 2023, with IND filing forecast for first half of 2024. First in-human Phase I/IIa trials are predicted shortly after in H1 of 2024, including pancreatic and other solid tumors with poor treatment options and life-expectancy.

Renovaro believes that RENB-DC11 could represent the most promising and effective strategy to achieve life-long remission for a number of common and deadly tumors.

Other Development Candidates

In addition to its lead oncology platform, Renovaro’s development pipeline includes a platform targeting infectious diseases, including:

• RENB-HV12 – An engineered allogeneic T-Cell vaccine, this therapeutic HIV vaccine candidate enhances immune infiltration, immune killing and immune surveillance. Potential pre-IND submission is planned for first half of 2024, with IND-submission expected in second half of 2024.
• RENB-HV21 – Leveraging allogeneic NK plus Gamma Delta T (“GDT”) cells as potential therapy for HIV, ENOB-HV21 shows promising preliminary results without confounding factors. Renovaro owns an exclusive license and has completed the Pre-IND submission, with a potential IND submission and human trials expected in 2024.
• RENB-HV01 – Caring Cross, a non-profit corporation, has shown that its proprietary CAR-T cells cure HIV in a mouse model. Studies in humans have begun. Renovaro has entered into a profit-sharing sublicense with Caring Cross and would share in profits if the product is commercialized.
• RENB-HB01 – This therapeutic approach aims to eliminate all HBV rapidly (“seek and kill”) with a two to three dose treatment regimen. It is expected to be applicable for early disease to maximize impact with low risk of toxicity. Pre-IND comments have been received from the FDA for its AAV-delivery system.
  LOI to Merge with GEDi Cube International Ltd.

On August 9, 2023, Renovaro announced its execution of a binding, exclusive letter of intent to merge a subsidiary with cutting-edge health AI company GEDi Cube International Ltd. The combined company is expected to create a potential multiplier effect to accelerate earlier diagnosis, more effective therapy, and precision in silico drug discovery.

GEDi Cube’s innovative technology, developed over nearly a decade, has already validated earlier diagnoses of lung cancer in humans at a leading university hospital. GEDi Cube has likewise created the early diagnosis technology for 12 additional cancers, including pancreatic and breast cancer.

“I believe joining forces with GEDi Cube could enhance the efficacy of our upcoming trials and speed up the discovery of novel treatment approaches, thereby extending our life-saving technology to more cancer patients and renewing hope for them and their families,” Dr. Mark Dybul, CEO of Renovaro, stated in the news release.

GEDi Cube is led by CEO Craig Rhodes, who brings to that company tremendous industry experience leading life sciences groups at industry leaders Intel, Oracle and NVIDIA.

Market Opportunity

Pancreatic cancer alone is diagnosed globally in approximately 495,000 people each year, including roughly 64,000 in the U.S. Nearly 466,000 of those patients die annually, including approximately 51,000 in the U.S. Because of limited treatment options, life expectancy is very poor – with an approximately 10% patient survival rate at five years after diagnosis.

The global pancreatic cancer treatment market was valued at $2.15 billion in 2021 and is projected to grow from $2.48 billion in 2022 to $6.85 billion by 2029, according to Fortune Business Insights. That growth represents a CAGR of 15.7% for the forecast period.

A separate report from Fortune Business Insights projects that the global HIV drug market will grow from $30.46 billion in 2021 to $45.58 billion in 2028, recording a CAGR of 5.9% over the forecast period.

According to GlobalData, the value of the market for hepatitis B treatment is forecast to experience a significant increase in the coming years, with revenues expected to grow from $1.6 billion in 2022 to $10.5 billion in 2029. That represents a very rapid CAGR of 30% over the period. An estimated 296 million people suffer from the condition worldwide.

Management Team

Dr. Mark Dybul is the CEO of Renovaro. He has served as a tenured professor in the Department of Medicine at Georgetown University Medical Center since June 2017. He also served as Faculty Co-Director of the Center for Global Health and Quality from 2017-2021. Dr. Dybul has worked on HIV and public health for nearly 30 years as a clinician, scientist, teacher and administrator, including as an architect and eventually the Global Ambassador of the U.S. President’s Emergency Plan for AIDS Relief and the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria from 2013 through May of 2017, and as the co-director of the Global Health Law Program at the O’Neill Institute for National and Global Health Law from 2009 through 2012. He is a member of the U.S. National Academy of Medicine.

Luisa Puche is the company’s CFO. She has served as a senior accounting and financial advisor and president of Puche Group LLC from 2015-2019. She served in various key executive roles, including Interim Chief Accounting Officer, at Brightstar Corp., a $10 billion global wireless device services provider. Ms. Puche began her career at Ernst & Young, where she served for approximately 10 years. Leveraging her broad global audit, advisory and corporate expertise, she has provided strong cross-functional leadership experience managing small and large projects for both publicly traded and privately held companies in various industries, including a global implementation of the latest revenue recognition accounting standard for Del Monte, as well as the global implementation of their SOX-404 program.

Francois Binette, Ph.D., is the Chief Operating Officer and Executive Vice President of Research & Development at Renovaro. He has over 25 years of product development expertise in Advanced Therapies and Regenerative Medicine. His broad industry experience spans a wide range of serious medical conditions, from orthopedics to ophthalmology, CNS and immuno-oncology. His career includes positions at Genzyme, Biosyntech, the DePuy Franchise of Johnson and Johnson, Medtronic and Lineage Cell Therapeutics. He received his Ph.D. from Laval University in Québec, followed by post-doctoral training at the Sanford-Burnham Institute in La Jolla and Harvard Medical School in Boston.

For more information, visit the company’s website at www.EnochianBio.com.

NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB